TriSalus Life Sciences (TLSI) to Release Earnings on Thursday

TriSalus Life Sciences (NASDAQ:TLSI) will announce its earnings results before the market opens on Thursday, November 14th. Analysts expect the company to announce earnings of ($0.37) per share for the quarter. Investors that wish to listen to the company’s earnings conference call can do so using this link.

TriSalus Life Sciences (NASDAQ:TLSI) last issued its earnings results on Wednesday, August 14th. The company reported ($0.21) earnings per share for the quarter. The firm had revenue of $7.36 million for the quarter. On average, analysts expect TriSalus Life Sciences to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

TriSalus Life Sciences Stock Up 4.0 %

Shares of TLSI opened at $4.16 on Thursday. The company has a 50-day moving average price of $4.46 and a two-hundred day moving average price of $6.05. The stock has a market cap of $121.93 million, a price-to-earnings ratio of -1.66 and a beta of 0.49. TriSalus Life Sciences has a 12 month low of $3.32 and a 12 month high of $10.42.

Wall Street Analyst Weigh In

TLSI has been the subject of several recent analyst reports. Northland Securities initiated coverage on TriSalus Life Sciences in a research note on Friday, October 25th. They set an “outperform” rating and a $12.50 price objective for the company. Northland Capmk upgraded shares of TriSalus Life Sciences to a “strong-buy” rating in a research note on Friday, October 25th. Finally, Oppenheimer began coverage on TriSalus Life Sciences in a report on Monday, September 16th. They set an “outperform” rating and a $10.00 price target for the company. Five investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $12.50.

Insiders Place Their Bets

In other TriSalus Life Sciences news, CEO Mary T. Szela purchased 7,520 shares of the stock in a transaction dated Thursday, September 12th. The stock was bought at an average price of $5.20 per share, for a total transaction of $39,104.00. Following the transaction, the chief executive officer now directly owns 377,382 shares in the company, valued at $1,962,386.40. This represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 32.80% of the company’s stock.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.